Ocera Therapeutics, Inc.
525 University Avenue
Suite 610
Palo Alto
California
94301
United States
Tel: 650-475-0158
Fax: 650-521-5677
Website: http://www.ocerainc.com/
Email: ashibata@ocerainc.com
79 articles about Ocera Therapeutics, Inc.
-
Mallinckrodt Completes Acquisition of Ocera Therapeutics and OCR-002, its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy
12/11/2017
The tender offer by a subsidiary of Mallinckrodt plc for all of the outstanding shares of Ocera common stock expired as scheduled at 12:00 midnight (Eastern) on December 8, 2017.
-
Mallinckrodt has agreed to buy Ocera Therapeutics in a deal that could hit $117M.
-
Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting
10/20/2017
The event will be on October 20-24, 2017, at the Washington Convention Center in Washington, D.C.
-
Ocera Therapeutics Reports Second Quarter 2017 Financial Results
8/2/2017
-
Ocera Therapeutics Initiates Phase IIa Study With Oral OCR-002 In Patients With Cirrhosis
6/1/2017
-
Ocera Therapeutics To Host KOL Conference Call On Hepatic Encephalopathy And Other Complications Of Liver Disease On Friday, June 2
5/26/2017
-
Ocera Therapeutics Reports First Quarter 2017 Financial Results And Provides Clinical Update
5/10/2017
-
Ocera Therapeutics Announces Presentation Of Data Showing OCR-002 Prevented Progression Of Fibrosis In Preclinical Model Of Non-Alcoholic Fatty Liver Disease (NAFLD)
4/13/2017
-
Bay Area's Ocera Therapeutics Plunges as Lead Drug Flunks Mid-Stage Hepatic Encephalopathy Study
1/30/2017
-
Ocera Therapeutics, Inc. To Present At The 2016 BIO International Convention
5/27/2016
-
Ocera Therapeutics, Inc. Announces Positive Phase 1 Results For Oral OCR-002 In Development For The Prevention Of Chronic Hepatic Encephalopathy
11/17/2015
-
Ocera Therapeutics, Inc. To Present At Stifel 2015 Healthcare Conference
11/10/2015
-
Ocera Therapeutics, Inc. Reports Third Quarter 2015 Financial Results
11/5/2015
-
Ocera Therapeutics, Inc. Highlights OCR-002 Data To Be Presented At The Annual Meeting Of American Association for Study of Liver Diseases (AASLD)
10/6/2015
-
Ocera Therapeutics, Inc. Initiates Phase 1 Clinical Trial Of Oral Drug Candidate OCR-002 For Prevention Of Hepatic Encephalopathy
9/17/2015
-
Ocera Therapeutics, Inc. To Present At The Rodman & Renshaw 17th Annual Global Investment Conference
9/2/2015
-
Ocera Therapeutics, Inc. To Be Honored At The 17th Annual American Liver Foundation's Salute To Excellence Awards Gala In San Francisco
5/4/2015
-
Ocera Therapeutics, Inc. Announces Change In Executive Team
5/4/2015
-
Ocera Therapeutics, Inc. Reports Pipeline Progress And First Quarter 2015 Financial Results
4/30/2015
-
Ocera Therapeutics, Inc. To Report Pipeline Progress And First Quarter 2015 Financial Results
4/23/2015